Benzinga | Sep 27, 2021 06:04AM EDT

ASLAN Pharmaceuticals Announces Positive Data Conclusively Establishing Proof Of Concept For ASLAN004 In Atopic Dermatitis

- Topline data from multiple-ascending-dose study supports a potentially differentiated safety and efficacy profile

- ASLAN004 achieved a statistically significant improvement (p<0.0251) versus placebo in the primary efficacy endpoint of percent change from baseline in EASI with significant improvements in other efficacy endpoints

- Well-tolerated with no cases of conjunctivitis in the expansion cohort

- On track to enroll first patient in global Phase 2b study in 4Q 21

- Management to host conference call and webcast today, 27 September, at 8am ET / 8pm SGT